SOX6 and glioblastoma: To understand the clinical relevance of top mutated novel genes, we analyzed the REMBRANDT [78] and TCGA GBM datasets for correlation of gene expression with patient survival (n = 329 and n = 348 tumor samples respectively): expression levels of SOX6, UST, QKI, PPP1R14C, TCF12, SPRED1, TEAD2, and NAV3 significantly correlated with patient survival in one or both of these independent datasets (p < 0.05, log-rank test, comparing patients with upper 30% vs lower 70% of expression levels, Fig. 5b–g).